"The US Food and Drug Administration (FDA) is investigating the "rare but serious" risk for slowed or difficult breathing in children 17 and younger treated with the opioid analgesic tramadol.
"This risk may be increased in children tr"...
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The adverse event data described below reflect the safety experience in over 7000 patients exposed to Campral for up to one year, including over 2000 Campral-exposed patients who participated in placebo-controlled trials.
Adverse Events Leading to Discontinuation
In placebo-controlled trials of 6 months or less, 8% of Campral-treated patients discontinued treatment due to an adverse event, as compared to 6% of patients treated with placebo. In studies longer than 6 months, the discontinuation rate due to adverse events was 7% in both the placebo-treated and the Campral-treated patients. Only diarrhea was associated with the discontinuation of more than 1% of patients (2% of Campral-treated vs. 0.7% of placebo-treated patients). Other events, including nausea, depression, and anxiety, while accounting for discontinuation in less than 1% of patients, were nevertheless more commonly cited in association with discontinuation in Campral-treated patients than in placebo-treated patients.
Common Adverse Events Reported in Controlled Trials
Common adverse events were collected spontaneously in some controlled studies and using a checklist in other studies. The overall profile of adverse events was similar using either method. Table 1 shows those events that occurred in any Campral treatment group at a rate of 3% or greater and greater than the placebo group in controlled clinical trials with spontaneously reported adverse events. The reported frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed, without regard to the causal relationship of the events to the drug.
Table 1: Events Occurring at a Rate of at Least 3% and
Greater than Placebo in any Campral Treatment Group in Controlled Clinical
Trials with Spontaneously Reported Adverse Events.
|Number of Patients (%) with Events|
|Campral 1332 mg/day||Campral 1998 mg/day1||Campral Pooled2||Placebo|
|Number of patients in Treatment Group||397||1539||2019||1706|
|Number (%) of patients with an AE||248 (62%)||910 (59%)||1231 (61%)||955 (56%)|
|Body as a Whole||121 (30%)||513 (33%)||685 (34%)||517 (30%)|
|Accidental Injury*†||17 ( 4%)||44 ( 3%)||70 ( 3%)||52 ( 3%)|
|Asthenia||29 ( 7%)||79 ( 5%)||114 ( 6%)||93 ( 5%)|
|Pain||6 ( 2%)||56 ( 4%)||65 ( 3%)||55 ( 3%)|
|Digestive System||85 (21%)||440 (29%)||574 (28%)||344 (20%)|
|Anorexia||20 ( 5%)||35 ( 2%)||57 ( 3%)||44 ( 3%)|
|Diarrhea||39 (10%)||257 (17%)||329 (16%)||166 (10%)|
|Flatulence||4 ( 1%)||55 ( 4%)||63 ( 3%)||28 ( 2%)|
|Nausea||11 ( 3%)||69 ( 4%)||87 ( 4%)||58 ( 3%)|
|Nervous System||150 (38%)||417 (27%)||598 (30%)||500 (29%)|
|Anxiety††**||32 ( 8%)||80 ( 5%)||118 ( 6%)||98 ( 6%)|
|Depression||33 ( 8%)||63 ( 4%)||102 ( 5%)||87 ( 5%)|
|Dizziness||15 ( 4%)||49 ( 3%)||67 ( 3%)||44 ( 3%)|
|Dry mouth||13 ( 3%)||23 ( 1%)||36 ( 2%)||28 ( 2%)|
|Insomnia||34 ( 9%)||94 ( 6%)||137 ( 7%)||121 ( 7%)|
|Paresthesia||11 ( 3%)||29 ( 2%)||40 ( 2%)||34 ( 2%)|
|Skin and Appendages||26 ( 7%)||150 (10%)||187 ( 9%)||169 (10%)|
|Pruritus||12 ( 3%)||68 ( 4%)||82 ( 4%)||58 ( 3%)|
|Sweating||11 ( 3%)||27 ( 2%)||40 ( 2%)||39 ( 2%)|
|†*includes events coded as “fracture” by sponsor;
††**includes events coded as “nervousness” by sponsor
1 includes 258 patients treated with acamprosate calcium 2000 mg/day, using a different dosage strength and regimen.
2 includes all patients in the first two columns as well as 83 patients treated with acamprosate calcium 3000 mg/day, using a different dosage strength and regimen.
In clinical trials, the safety profile in subjects treated with Campral concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications. Patients taking Campral concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.
Other Events Observed During the Premarketing Evaluation of Campral
Following is a list of terms that reflect treatment-emergent adverse events reported by patients treated with Campral in 20 clinical trials (4461 patients treated with Campral, 3526 of whom received the maximum recommended dose of 1998 mg/day for up to one year in duration). This listing does not include those events already listed above; events for which a drug cause was considered remote; event terms which were so general as to be uninformative; and events reported only once which were not likely to be acutely life-threatening.
Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring in at least 1/100 patients (only those not already listed in the summary of adverse events in controlled trials appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.
Body as a Whole – Frequent: headache, abdominal pain, back pain, infection, flu syndrome, chest pain, chills, suicide attempt; Infrequent: fever, intentional overdose, malaise, allergic reaction, abscess, neck pain, hernia, intentional injury; Rare: ascites, face edema, photosensitivity reaction, abdomen enlarged, sudden death.
Cardiovascular System – Frequent: palpitation, syncope; Infrequent: hypotension, tachycardia, hemorrhage, angina pectoris, migraine, varicose vein, myocardial infarct, phlebitis, postural hypotension; Rare: heart failure, mesenteric arterial occlusion, cardiomyopathy, deep thrombophlebitis, shock.
Digestive System – Frequent: vomiting, dyspepsia, constipation, increased appetite; Infrequent: liver function tests abnormal, gastroenteritis, gastritis, dysphagia, eructation, gastrointestinal hemorrhage, pancreatitis, rectal hemorrhage, liver cirrhosis, esophagitis, hematemesis, nausea and vomiting, hepatitis; Rare: melena, stomach ulcer, cholecystitis, colitis, duodenal ulcer, mouth ulceration, carcinoma of liver.
Metabolic and Nutritional Disorders – Frequent – peripheral edema, weight gain; Infrequent: weight loss, hyperglycemia, SGOT increased, SGPT increased, gout, thirst, hyperuricemia, diabetes mellitus, avitaminosis, bilirubinemia; Rare: alkaline phosphatase increased, creatinine increased, hyponatremia, lactic dehydrogenase increased.
Nervous System – Frequent –somnolence, libido decreased, amnesia, thinking abnormal, tremor, vasodilatation, hypertension; Infrequent: convulsion, confusion, libido increased, vertigo, withdrawal syndrome, apathy, suicidal ideation, neuralgia, hostility, agitation, neurosis, abnormal dreams, hallucinations, hypesthesia; Rare: alcohol craving, psychosis, hyperkinesia, twitching, depersonalization, increased salivation, paranoid reaction, torticollis, encephalopathy, manic reaction.
Urogenital System – Frequent: impotence; Infrequent – metrorrhagia, urinary frequency, urinary tract infection, sexual function abnormal, urinary incontinence, vaginitis; Rare: kidney calculus, abnormal ejaculation, hematuria, menorrhagia, nocturia, polyuria, urinary urgency.
The following adverse reactions have been identified during post approval use of Campral. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Serious Adverse Events Observed During the Non-US Postmarketing Evaluation of Campral (acamprosate calcium)
The serious adverse event of acute kidney failure has been reported to be temporally associated with Campral treatment in at least 3 patients and is not described elsewhere in the labeling.
Read the Campral (acamprosate calcium) Side Effects Center for a complete guide to possible side effects
Acamprosate does not affect the pharmacokinetics of alcohol. The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [see CLINICAL PHARMACOLOGY].
Read the Campral Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 2/15/2012
Additional Campral Information
Campral - User Reviews
Campral User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.